Rezolute Updates on FDA Meeting for Congenital HI Program, Critical Catalyst Delivered

What happened

Rezolute announced outcomes from a Type B FDA meeting on March 17, 2026, regarding its failed sunRIZE Phase 3 study for congenital hyperinsulinism. This follows the December 2025 pivotal trial miss that triggered an 80-90% stock collapse and reshaped the company into a distressed single-asset story. The meeting was a key near-term catalyst identified in prior analysis to determine any salvage path for the congenital program. While the release confirms the meeting occurred, it omits specific FDA feedback, leaving investors to parse subsequent disclosures for regulatory stance. This update is pivotal as it directly influences whether Rezolute can revive its congenital ambitions or must double down on the tumor HI upLIFT trial.

Implication

The FDA meeting outcome is a binary catalyst that could either support a salvage plan for congenital HI, aligning with the bull scenario and potential upside to $6.00, or confirm rejection, pushing the stock toward the bear case near $1.25. Without disclosed specifics, the high burn rate of ~$70M annually threatens cash runway into mid-2027, necessitating disciplined cost cuts if congenital hopes fade. The upLIFT tumor HI program remains a fallback, but any negative spillover from congenital setbacks could erode investor confidence and delay timelines. Legal overhangs from securities investigations add tail risk, complicating financing flexibility. Investors must now monitor management's next steps for regulatory clarity and cost control to assess asymmetric risk-reward.

Thesis delta

The expected Q1 2026 FDA feedback has been delivered, moving the thesis from anticipation to evaluation of congenital HI's salvage potential. If outcomes hint at a viable path, probability could shift toward the bull scenario; if vague or negative, the bear case gains traction, emphasizing tumor HI as the sole near-term value driver. Investors should update models based on forthcoming details, as this update reduces uncertainty but requires critical scrutiny beyond management's optimistic framing.